SUNRISE, Fla., July 27, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today that their clinical paper has been accepted for publication in a prominent peer reviewed medical journal. The American Heart Journal has accepted for publication "A Double-blind, Randomized, Controlled, Multicenter Study to Assess the Safety and Cardiovascular Effects of Skeletal Myoblast Implantation by Catheter Delivery in Patients with Chronic Heart Failure Following Myocardial Infarction." Results of part one of the MARVEL phase II/III study were previously presented by Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University. In comparison with the placebo group, myoblast therapy was associated with sustained (6 months) improvements in exercise capacity distance of greater than 90 meters, an increase that would be of great importance to patients if replicated in larger studies.
